Innovation Pharmaceuticals Conducting Full Data Analysis of Phase 2 Brilacidin COVID-19 Trial Results to Support Brilacidin’s Potential Inclusion in Government-Sponsored COVID-19 Trials (IPIX)

Additionally, new in vitro data also show Brilacidin targets both viral proteins and host factors, suggesting Brilacidin would be less

Read more

Cannabics Pharmaceuticals receives “Intention to Grant a European Patent” notice for its System and Method for High Throughput Screening of Cancer Cells patent application

PR Newswire TEL AVIV, Israel and BETHESDA, Maryland, Oct. 27, 2020 TEL AVIV, Israel and BETHESDA, Maryland, Oct. 27, 2020 /PRNewswire/ — Cannabics Pharmaceuticals Inc.

Read more

Screening of 11,552 Compounds Identifies Innovation Pharmaceuticals’ Brilacidin as One of the Most Promising Potential Inhibitors of the Novel Coronavirus COVID-19

WAKEFIELD, Mass., April 20, 2020 (GLOBE NEWSWIRE) — Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased

Read more